| Don E Asberry, MD | |
|
1 Medical Park Blvd, Bristol, TN 37620-7430 | |
| (423) 844-3220 | |
| (423) 844-3114 |
| Full Name | Don E Asberry |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 18 Years |
| Location | 1 Medical Park Blvd, Bristol, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356522676 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 45876 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellmont Bristol Regional Medical Center | Bristol, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Highlands Pathology Consultants, P.c. | 3173515715 | 8 |
News Archive
As the SARS-CoV-2 continues to spread worldwide and cause disease and death on a devastating scale, genomic sequencing has become a primary method of keeping track of emerging variants and new outbreaks. A new medRxiv* preprint explores the role of nanopore sequencing in this effort.
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Level II Trauma Center Accreditation status has been granted to one additional hospital in Pennsylvania for the period from October 1, 2010 through September 30, 2011:
This is the point of a new report by the Institute of Medicine, Advancing Oral Health in America, which underscores a public health crisis that has persisted more than a decade after the U.S. Surgeon General called for aggressively reversing the "silent epidemic" of America's oral health disparity. Many of the most pernicious oral health diseases are highly preventable and treatable.
› Verified 2 days ago
| Entity Name | Highlands Pathology Consultants, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063498970 PECOS PAC ID: 3173515715 Enrollment ID: O20040401001430 |
News Archive
As the SARS-CoV-2 continues to spread worldwide and cause disease and death on a devastating scale, genomic sequencing has become a primary method of keeping track of emerging variants and new outbreaks. A new medRxiv* preprint explores the role of nanopore sequencing in this effort.
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Level II Trauma Center Accreditation status has been granted to one additional hospital in Pennsylvania for the period from October 1, 2010 through September 30, 2011:
This is the point of a new report by the Institute of Medicine, Advancing Oral Health in America, which underscores a public health crisis that has persisted more than a decade after the U.S. Surgeon General called for aggressively reversing the "silent epidemic" of America's oral health disparity. Many of the most pernicious oral health diseases are highly preventable and treatable.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Don E Asberry, MD 2175 Highway 75, Suite 4, Blountville, TN 37617 Ph: (423) 323-5290 | Don E Asberry, MD 1 Medical Park Blvd, Bristol, TN 37620-7430 Ph: (423) 844-3220 |
News Archive
As the SARS-CoV-2 continues to spread worldwide and cause disease and death on a devastating scale, genomic sequencing has become a primary method of keeping track of emerging variants and new outbreaks. A new medRxiv* preprint explores the role of nanopore sequencing in this effort.
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Level II Trauma Center Accreditation status has been granted to one additional hospital in Pennsylvania for the period from October 1, 2010 through September 30, 2011:
This is the point of a new report by the Institute of Medicine, Advancing Oral Health in America, which underscores a public health crisis that has persisted more than a decade after the U.S. Surgeon General called for aggressively reversing the "silent epidemic" of America's oral health disparity. Many of the most pernicious oral health diseases are highly preventable and treatable.
› Verified 2 days ago
David R Hudgens, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Park Blvd, Bristol, TN 37620 Phone: 423-844-3220 Fax: 423-844-3114 | |
Dr. Michael Wayne Rentz, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Park Blvd, Bristol, TN 37620 Phone: 423-844-3220 Fax: 423-844-3114 |